Close Menu

Waters

The company posted revenues of $460.4 million compared to $430.5 million in Q1 2014, beating the average Wall Street estimate of $445.3 million.

The amendment to a 2013 debt financing agreement will increase revolving commitments to $1.3 billion, extend maturity of loans, and adjust interest rates and fees.

Interest in detection directly from specimens and antibiotic resistance is leading some researchers to look at methods likeREIMSand MRM-MS.

The agency approved the Acquity UPLC I-Class IVD/Xevo TQ-S IVD LC-MS for clinical analysis of various targets.

Many of the meeting's proteomics presentations concerned not so much mass spec analysis itself as the refinement of processes and workflows leading up to it.

PerkinElmer's liquid and gas chromatography portfolio will be standardized on Waters' Empower Software.

The company's total revenues increased to $584 million from $565 million in the prior-year period, besting the consensus analyst estimate of $582 million.

From research collaborations to corporate acquisitions, attention from the broader scientific community highlighted the field's capabilities and limitations.

Mass spec instrumentation showed solid growth in Q3, with particular strength in academic and government markets.

NEW YORK (GenomeWeb News) – Waters today reported that its revenues in the third quarter were up 8 percent year over year, driven by broad-based demand for its instrument systems.

Pages

According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.

The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.

A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.

In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.